Evaluating Iodine-124 PET Imaging for Lesion Dosimetry in Metastatic Thyroid Carcinoma
Led by Memorial Sloan Kettering Cancer Center · Updated on 2026-09-10
75
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating a new diagnostic imaging test using positron emission tomography PET with a radioactive form of iodine called iodine-124 in patients with metastatic thyroid carcinoma. The study aims to measure the amount of radioactive iodine uptake in cancer lesions to determine if radioiodine therapy should continue or if alternative treatments are needed. This is a phase 1 diagnostic trial led by Memorial Sloan Kettering Cancer Center.
Participants will receive injections of rhTSH on two consecutive days followed by an oral dose of iodine-124, ranging from 4 to 7 mCi, to allow imaging of tumor uptake. Up to four whole-body PETCT scans will be performed at approximately 24, 48, and 120 hours after iodine-124 administration using specialized PET scanners. A subset of 10 patients may undergo additional PET scans during radioiodine therapy to compare tracer uptake before and during treatment.
During the study, participants will undergo multiple PETCT imaging sessions to assess radioactive iodine uptake and clearance in tumor lesions. Researchers will monitor lesion response over a 1-year period using these imaging results. The study involves close observation and data collection through imaging to evaluate the diagnostic value of iodine-124 PET in guiding therapy decisions. The total study duration extends through 2027, with ongoing assessments based on imaging data.
CONDITIONS
Brief Title
Lesion Dosimetry With Iodine-124 in Metastatic Thyroid Carcinoma
Research Team
R
Ravinder Grewal, MD
S
Steven Larson, MD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
Factors
Iodine-124 PET/CT imaging
Iodine-131 planar scintigraphy
What it is
An investigational dosimetry approach using Iodine-124 PET/CT scans to measure radioiodine uptake in metastatic lesions before 131I therapy.
Conventional pre-therapeutic dosimetry using planar scintigraphy (or SPECT) with diagnostic Iodine-131 to estimate lesion radioiodine uptake and guide 131I therapy.
Patients outside the trial typically receive dosimetry with Iodine-131 planar scintigraphy before 131I therapy.
Primary use
To provide precise, lesion-specific radiation dose estimates to personalize 131I therapy in metastatic thyroid carcinoma.
To estimate overall and lesion-based iodine uptake, typically providing whole-body dosimetry for 131I therapy planning.
How it is performed
Participants receive injections of recombinant human TSH and a single oral dose of Iodine-124, followed by up to four PET/CT scans at several time points.
Patients receive a small oral dose of Iodine-131 for diagnostic imaging, followed by planar (or SPECT) scans to assess radioiodine uptake.
Evidence status
Emerging evidence supports the use of Iodine-124 PET/CT for more accurate, lesion-specific dosimetry than conventional methods.
Widely used with established utility, but provides less precise lesion-by-lesion dose estimates compared to advanced PET/CT-based methods.
Important limitations
Limited availability outside research centers, more resource-intensive, and requires access to a PET/CT facility with Iodine-124 supply.
Lower spatial resolution, potential overlap of lesions, and less accurate quantification for heterogeneous metastatic disease.
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
Who Can Participate
Age: 18Years +
All Genders
Eligibility Criteria
You may qualify if you...
Adults with thyroid carcinoma confirmed by pathology
Adults who have undergone total thyroidectomy
Adults with metastatic or suspected metastatic thyroid carcinoma or undergoing re-induction therapy protocols
Planning to receive radioiodine therapy if persistent radioiodine-avid metastases are present
Measurable disease documented within the past six months by imaging (ultrasound, MRI, FDG PET/CT, or CT)
You will not qualify if you...
Under 18 years of age
Pregnant patients
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Imaging and Dosimetry
Duration - Several days
Participants receive rhTSH injections followed by an oral dose of iodine-124 and undergo up to four PET/CT scans over several days to measure radioactive iodine uptake in cancer lesions.
Up to 4 PET/CT scans
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Similar Trials
International Observational Study on Children and Adolescents With Very Rare Tumors
Study of Contrast-Enhanced Ultrasound to Improve Diagnosis of Thyroid Nodules Using Two Scoring Methods
Study of Diagnostic and Treatment Approaches for Adults with Thyroid Conditions
Including Hypothyroidism, Hyperthyroidism, Benign Nodules, and Thyroid Cancer
Study of Circulating Biomarkers Using Blood Tests in Adults with Advanced Thyroid Cancer
Comparing Blood-Based Molecular Profiles to Tumor Tissue Analysis for Treatment Decisions
A Clinical Trial to Preserve Neck Function During Thyroid Surgery
Comparing Thermal Ablation and Lobectomy for Benign Thyroid Nodules
in Patients with Unilateral Thyroid Cancer
International Registry for Pleuropulmonary Blastoma and DICER1-Related Conditions Observational Study
Study on Postoperative Laryngopharyngeal Injury and Hoarseness After General Anesthesia With Tracheal Intubation
A Retrospective Analysis of Risk Factors and Patient Outcomes
Evaluating Iodine-124 PET Imaging for Lesion Dosimetry in Metastatic Thyroid Carcinoma
Evaluation of Nanosecond Pulsed Field Ablation for Treating T1N0M0 Papillary Thyroid Carcinoma Using the CellFX System
Open-label Study of Oral S241656 with or without Other Anti-Cancer Drugs in Adult Patients with RASMAPK Mutation-Positive Advanced Solid Tumors
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
The use of single-timepoint images to link administered radioiodine activity (MBq) to a prescribed lesion radiation-absorbed dose (cGy): a regression-based prediction interval tool for the management of well-differentiated thyroid cancer patients.
Audrey Mauguen, Ravinder K Grewal, Finn Augensen...